

Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Data from the KEYNOTE-021 trial evaluating pembrolizumab with carboplatin/pemetrexed versus carboplatin/pemetrexed alone indicated a \_\_\_\_\_ overall response rate with the addition of pembrolizumab.
  - a. 20%
  - b. 30%
  - c. 55%
2. The Phase IIb LUX-Lung 7 study evaluating afatinib versus gefitinib as first-line therapy for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) demonstrated superior outcomes with afatinib regarding which of the following study endpoints?
  - a. Median progression-free survival (PFS)
  - b. Objective response rate
  - c. Both a and b
  - d. None of the above
3. The CREATE-X trial investigating the addition of capecitabine to standard adjuvant therapy for women with HER2-negative breast cancer who had residual invasive disease after neoadjuvant chemotherapy demonstrated \_\_\_\_\_ with capecitabine.
  - a. A significant improvement in disease-free survival
  - b. No benefit in overall survival
  - c. Both a and b
4. The Phase III MA17R trial evaluating the extension of adjuvant letrozole for 5 years after the completion of an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen for patients with early-stage breast cancer demonstrated no improvement in disease-free survival with the extension of aromatase inhibitor therapy.
  - a. True
  - b. False
5. Initial results from the Phase III NEMO study in unresectable or metastatic NRAS mutation-positive cutaneous melanoma indicated improved PFS with \_\_\_\_\_ compared to dacarbazine.
  - a. Binimetinib
  - b. Ribociclib
  - c. Trametinib
6. Results from the Phase II STRIVE trial for men with castration-resistant prostate cancer showed a significant reduction in the risk of disease progression with \_\_\_\_\_ compared to bicalutamide.
  - a. Enzalutamide
  - b. Abiraterone
  - c. Neither a nor b
7. Results of the randomized Phase III CheckMate 025 trial for patients with advanced renal cell carcinoma \_\_\_\_\_ a statistically significant improvement in overall survival with nivolumab compared to everolimus.
  - a. Demonstrated
  - b. Did not demonstrate
8. In the Phase II ECOG-E2408 trial of bendamustine/rituximab (BR) with or without bortezomib (V) followed by rituximab with or without lenalidomide for patients with previously untreated high-risk follicular lymphoma, the complete remission rate with BVR induction therapy was \_\_\_\_\_ to that with BR alone.
  - a. Significantly superior
  - b. Equivalent
  - c. Inferior

Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. The SWOG-S0777 trial evaluating bortezomib/lenalidomide/dexamethasone (RVD) versus lenalidomide/dexamethasone for patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant demonstrated \_\_\_\_\_ in PFS with RVD.
- a. A significant improvement
  - b. No improvement
10. The Phase II HERACLES trial evaluating the combination of \_\_\_\_\_ demonstrated an objective response rate of 30% in patients with HER2-amplified metastatic colorectal cancer.
- a. T-DM1 and trastuzumab
  - b. Lapatinib and trastuzumab
  - c. Lapatinib and T-DM1